SpotitEarly recently announced a strategic partnership with Fox Chase Cancer Center. This collaboration focuses on validating a breakthrough Early Cancer Detection Technology. The startup uses artificial intelligence and trained dogs to find cancer signatures in breath. Both teams will launch clinical trials to test the effectiveness of this screening. Specifically, the first study will evaluate patients with suspected lung cancer. This partnership aligns with SpotitEarly’s goal to expand its presence across the United States.
Fox Chase Cancer Center is one of the national leaders in oncology research and innovation. They are to lead a multi-year study to assess the performance of this test. They can bring clinical expertise to this field along with innovative tests that can lead to improved patient results. The test is non-invasive and easy for a patient to do at home. Earlier tests pointed to an overall sensitivity rate of ~94% across four common cancers. This high level of precision offers great hope for future medical applications.
“At Fox Chase, we are committed to pushing the boundaries of cancer research through bold and collaborative partnerships. SpotitEarly brings an unconventional yet scientifically promising approach to early detection, and we see tremendous potential in their innovative product and technology when combined with our robust clinical expertise,” said Sangeeta Bardhan Cook, PhD, MBA, and Chief Innovation Officer, Fox Chase Cancer Center.
The company uses a proprietary platform called LUCID to monitor canine signals. These behavioral signs are translated into a standardized report for doctors to review. This bio-AI hybrid approach creates a repeatable and scalable way to screen millions. Consequently, people can access life-saving information much faster than traditional methods allow.
Expanding the Reach of Medical Innovation
This news follows another partnership with Hackensack Meridian Health in New Jersey. SpotitEarly continues to grow its network of physicians and medical resources rapidly. These clinical trials are a vital step toward full commercialization in the U.S. market.
“Working with Fox Chase Cancer Center was a natural next step for our organization as we continue to grow our footprint in the states. As a leader in cancer research, their team will provide us with access to a vast network of physicians and resources to collaborate on groundbreaking clinical trials and treatments,” said Shlomi Madar, PhD, CEO of SpotitEarly.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
